Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Buy the dip in this major pharma stock - Citi
May 6, 2024 9:30 AM EDTCiti analysts said in a note Monday that they believe history shows the dip in one major pharmaceutical company's shares should be bought.
The investment bank said Novo Nordisk (NYSE: NVO) remains Buy-rated, while the firm also maintained a Dkr975.00 price target on the stock.... More
Novo Nordisk, Eli Lilly drop on Amgen competition concerns
May 3, 2024 7:15 AM EDT(Updated - May 3, 2024 7:48 AM EDT)
Shares of Novo Nordisk (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY) are down premarket Friday as competition in the GLP-1 market. Amgen (NASDAQ: AMGN) disclosed that it looked at AMG133's unblinded phase 2 interim trial and came away confident in 133's differentiated... More
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
